Abstract| Volume 87, ISSUE 9, SUPPLEMENT , S18-S19, May 01, 2020

The Association Between Medication, Dopamine Function, and Long-Term Symptom Severity in the Matured and Developing Brain in ADHD

      We previously demonstrated in a randomized clinical trial (RCT) that methylphenidate (MPH) treatment in boys, but not men, with attention-deficit/ hyperactivity disorder (ADHD) alters dopamine function 1 week after RCT end. However, changes in dopamine function did not correlate with clinical outcome. Here, we assess whether clinical outcome at longitudinal follow-up is predicted by baseline dopamine function and whether clinical outcome is modulated by medication.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect